T10 soluble complement receptor 1: Began a Phase I, dose-escalating trial in patients scheduled for thrombolytics or angioplasty, to determine safety and pharma

T Cell Sciences Inc. (TCEL),

Read the full 56 word article

How to gain access

Continue reading with a
two-week free trial.